Episodes (Page 9)
✨
Merck seeks to replace Keytruda revenue, Novartis navigates patent expirations.
✨
Airway Therapeutics CEO discusses zelpultide alfa for preventing BPD in preterm infants.
✨
FDA hiring increases but net employee losses continue, impacting workload.
✨
EU's Green Deal rollback and US state-level mandates create sustainability uncertainty.
Steve Ramus
✨
AstraZeneca plans major China investment; Novartis warns of early trial competition.
✨
AstraZeneca pledges significant China investment; Novartis execs warn on trial competition.
✨
Discussion on center director roles in FDA's CNPV review process.
✨
Senti Bio CEO discusses programmable cell therapy for AML toxicity.
✨
J&J's oncology prospects and GSK's Rapt acquisition are discussed.
✨
J&J's oncology pipeline and GSK's acquisition of Rapt are highlighted.
✨
Trends and topics from the J.P. Morgan Healthcare Conference are reviewed.
✨
FDA's novel drug review speed remained steady in 2025.
Bridget Silverman
Derrick Gingery
Nielsen Hobbs
Sue Sutter
✨
Herantis Pharma CEO discusses unmet needs in Parkinson's disease.
Antti Vuolanto
✨
Novartis warns against protectionist global trade policies.
✨
J.P. Morgan expresses optimism; Scrip analyzes 2026 M&A trends.
✨
J.P. Morgan conference shows industry optimism for 2026.
✨
Concerns raised about FDA's Commissioner's National Priority Voucher Program.
Derrick Gingery
Nielsen Hobbs
Sue Sutter
✨
Scrip's outlook on the 2026 global biopharma industry.
✨
Oral Wegovy launched in the US market.
✨
Oral Wegovy launches in the US.